|
|
Article: Indiplon: A short-acting GABA-A receptor agonist sedative hypnotic for the treatment of insomnia
- Article from:
- Formulary
- Article date:
- July 1, 2006
- Author:
-
;
|
Copyright informationCopyright Advanstar Communications, Inc. Jul 2006. Provided by ProQuest LLC. (Hide copyright information)
|
Abstract
A number of clinical approaches are utilized in managing insomnia. Indiplon (Pfizer) is a selective non-benzodiazepine sedative hypnotic under consideration by FDA for the treatment of insomnia. Like other agents in its class, indiplon binds selectively to the GABA-A receptors in the brain, promoting sleep. Clinical studies have demonstrated improved efficacy in the treatment of sleep initiation and sleep maintenance with indiplon therapy in patients with acute and chronic insomnia. (Formulary. 2006;41:316-321.)
More than a third of American adults have experienced occasional insomnia or sleep disruption.1 Insomnia is a common disorder characterized by difficulty falling asleep, ...
Related newspaper, magazine, and journal articles:
|
|
Article: Insomnia could be sign of depression or anxiety.(Mind News)(Survey)
Annals of the American Psychotherapy Association;
December 22, 2007 ;
186 words
......gathered on the link between insomnia and mental health problems...adults, those suffering from chronic insomnia were also more likely to...not report suffering from insomnia. Additionally, participants...depression also suffer from insomnia as a side effect, but insomnia itself is ...
|
|